CY1117543T1 - Αναστολεις βητα-σεκρετασης - Google Patents

Αναστολεις βητα-σεκρετασης

Info

Publication number
CY1117543T1
CY1117543T1 CY20161100327T CY161100327T CY1117543T1 CY 1117543 T1 CY1117543 T1 CY 1117543T1 CY 20161100327 T CY20161100327 T CY 20161100327T CY 161100327 T CY161100327 T CY 161100327T CY 1117543 T1 CY1117543 T1 CY 1117543T1
Authority
CY
Cyprus
Prior art keywords
beta
secretion inhibitors
inhibitors
neurodegenerative
acylguanidins
Prior art date
Application number
CY20161100327T
Other languages
English (en)
Inventor
Yuri Bukhtiyarov
Salvacion Cacatian
Lawrence Wayne Dillard
Cornelia Dorner-Ciossek
Klaus Fuchs
Lanqi Jia
Deepak S Lala
Angel Morales-Ramos
Georg Rast
Jonathan Reeves
Suresh B Singh
Shankar Venkatraman
Zhenrong Xu
Jing Yuan
Yi Zhao
Yajun Zheng
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of CY1117543T1 publication Critical patent/CY1117543T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02—Sulfinic acids; Derivatives thereof
    • C07C313/06—Sulfinamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
    • C07C331/02—Thiocyanates
    • C07C331/14—Thiocyanates having sulfur atoms of thiocyanate groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/687—Unsaturated compounds containing a keto groups being part of a ring containing halogen
    • C07C49/697—Unsaturated compounds containing a keto groups being part of a ring containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
    • C07C49/747—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
    • C07C49/755—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/93—Spiro compounds
    • C07C2603/94—Spiro compounds containing "free" spiro atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με σπειροκυκλικές ακυλογουανιδίνες και με τη χρήση τους ως αναστολέων της δράσης του ενζύμου β-σεκρετάσης (BACE1), με φαρμακευτικές συνθέσεις που περιέχουν αυτές και με μεθόδους χρήσης αυτών ως θεραπευτικών παραγόντων στη θεραπευτική αντιμετώπιση νευροεκφυλιστικών διαταραχών, διαταραχών που χαρακτηρίζονται από έκπτωση των γνωστικών λειτουργιών, μείωση των γνωστικών λειτουργιών, άνοια και παθήσεων που χαρακτηρίζονται από παραγωγή συσσωρεύσεων β-αμυλοειδούς.
CY20161100327T 2012-03-05 2016-04-19 Αναστολεις βητα-σεκρετασης CY1117543T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261606786P 2012-03-05 2012-03-05
EP13710937.7A EP2822930B1 (en) 2012-03-05 2013-03-04 Inhibitors of beta-secretase

Publications (1)

Publication Number Publication Date
CY1117543T1 true CY1117543T1 (el) 2017-04-26

Family

ID=47902355

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100327T CY1117543T1 (el) 2012-03-05 2016-04-19 Αναστολεις βητα-σεκρετασης

Country Status (40)

Country Link
US (4) US8981112B2 (el)
EP (1) EP2822930B1 (el)
JP (1) JP6161643B2 (el)
KR (1) KR20140138774A (el)
CN (1) CN104271558B (el)
AP (1) AP4029A (el)
AR (1) AR090241A1 (el)
AU (2) AU2013230523B2 (el)
BR (1) BR112014021269A2 (el)
CA (1) CA2864143C (el)
CL (1) CL2014002334A1 (el)
CO (1) CO7091177A2 (el)
CY (1) CY1117543T1 (el)
DK (1) DK2822930T3 (el)
EA (1) EA024995B1 (el)
EC (1) ECSP14020640A (el)
ES (1) ES2568928T3 (el)
GE (1) GEP20176799B (el)
HR (1) HRP20160415T1 (el)
HU (1) HUE027289T2 (el)
IL (1) IL233887A (el)
IN (1) IN2014DN06710A (el)
MA (1) MA35945B1 (el)
ME (1) ME02390B (el)
MX (1) MX353432B (el)
MY (1) MY171091A (el)
NZ (1) NZ629239A (el)
PE (1) PE20141972A1 (el)
PH (1) PH12014501963A1 (el)
PL (1) PL2822930T3 (el)
RS (1) RS54730B1 (el)
SG (1) SG11201404600VA (el)
SI (1) SI2822930T1 (el)
SM (1) SMT201600114B (el)
TN (1) TN2014000326A1 (el)
TW (1) TWI557112B (el)
UA (1) UA113641C2 (el)
UY (1) UY34654A (el)
WO (1) WO2013134085A1 (el)
ZA (1) ZA201405846B (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2616728T3 (es) 2008-05-23 2017-06-14 Siwa Corporation Procedimientos y composiciones para facilitar la regeneración
AU2010223937B2 (en) 2009-03-13 2015-01-22 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
WO2011106414A1 (en) 2010-02-24 2011-09-01 Dillard Lawrence W Inhibitors of beta-secretase
TWI557112B (zh) 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β－分泌酶抑制劑
WO2013169531A1 (en) 2012-05-09 2013-11-14 Boehringer Ingelheim International Gmbh Methods for making oxetan-3-ylmethanamines
TW201422592A (zh) * 2012-08-27 2014-06-16 Boehringer Ingelheim Int β－分泌酶抑制劑
JP2015532282A (ja) 2012-09-28 2015-11-09 ヴァイティー ファーマシューティカルズ，インコーポレイテッド β−セクレターゼの阻害剤
WO2014081558A1 (en) 2012-11-21 2014-05-30 Boehringer Ingelheim International Gmbh PROCESS FOR MAKING N-SULFINYL a-AMINO AMIDES
ES2908203T3 (es) 2014-09-19 2022-04-28 Siwa Corp Anticuerpos anti-age para el tratamiento de inflamación y trastornos autoinmunes
UY36347A (es) 2014-10-07 2016-04-01 Astrazeneca Ab Compuestos y su uso como inhibidores de bace
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
WO2017143073A1 (en) 2016-02-19 2017-08-24 Siwa Corporation Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)
EP3443007A1 (en) 2016-04-15 2019-02-20 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
WO2017222535A1 (en) 2016-06-23 2017-12-28 Siwa Corporation Vaccines for use in treating various diseases and disorders
US11077108B2 (en) * 2016-09-07 2021-08-03 The Regents Of The University Of California Allosteric corticotropin-releasing factor receptor 1 (CRFR1) antagonists that decrease p-tau and improve cognition
EP3609923A1 (en) 2017-04-13 2020-02-19 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
EP3946606B1 (en) 2019-03-27 2025-01-01 Insilico Medicine IP Limited Bicyclic jak inhibitors and uses thereof
US12297244B2 (en) 2019-06-05 2025-05-13 Rensselaer Polytechnic Institute Systems and methods for inhibiting γ-secretase production of amyloid-β peptides
BE1027699B1 (fr) * 2021-01-28 2022-04-01 Trasis S A Procédé de purification de macro-agrégats de sérumalbumine humaine radiomarqués
CN113082209A (zh) * 2021-03-31 2021-07-09 中国科学技术大学 Cd4+t细胞源性bace1、ep2、ep4作为阿尔茨海默病治疗靶点的应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5745185A (en) 1980-07-21 1982-03-13 Eisai Co Ltd Hydantoin derivative and its preparation
AU655666B2 (en) 1991-08-28 1995-01-05 Pharmacia & Upjohn Company Spirocyclic benzopyran imidazolines
CA2189634A1 (en) 1994-05-06 1995-11-16 John J. Baldwin Combinatorial dihydrobenzopyran library
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2005058311A1 (en) 2003-12-15 2005-06-30 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
CN1968945A (zh) 2004-06-16 2007-05-23 惠氏公司 用于抑制β分泌酶的氨基－5,5－二苯基咪唑酮衍生物
CN1997646A (zh) 2004-06-16 2007-07-11 惠氏公司 作为β－分泌酶抑制剂的二苯基咪唑并嘧啶胺和二苯基咪唑并咪唑胺
CA2583342A1 (en) 2004-10-13 2006-04-27 Merck And Co., Inc. Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer's disease
MX2007016182A (es) 2005-06-14 2008-03-07 Schering Corp Inhibidores de aspartil proteasas.
WO2006138192A1 (en) 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
TW200738683A (en) 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
CN101213183A (zh) 2005-06-30 2008-07-02 惠氏公司 氨基-5-(6元)杂芳基咪唑酮化合物和在β-分泌酶调节中的用途
TW200730523A (en) 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
JP4870162B2 (ja) 2005-07-29 2012-02-08 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 蒸気アイロンからの蒸気の噴出を生成する方法
KR20080050430A (ko) 2005-09-26 2008-06-05 와이어쓰 베타-세크레타제 (ｂａｃｅ) 억제제로서아미노-5-[4-(디플루오로메톡시)페닐]-5-페닐이미다졸론화합물
EP1942105B8 (en) 2005-10-25 2014-08-13 Shionogi&Co., Ltd. Aminodihydrothiazine derivative
US7872009B2 (en) 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
DE102005057688A1 (de) 2005-12-01 2007-06-14 Endress + Hauser Flowtec Ag Vorrichtung zur Bestimmung und/oder Überwachung des Massedurchflusses eines gasförmigen Mediums
CA2634037A1 (en) 2005-12-19 2007-07-12 Wyeth 2-amino-5-piperidinylimidazolone compounds and use thereof for .beta.-secretase modulation
EP1974278A4 (en) 2005-12-20 2012-01-04 Fieldbus Foundation SYSTEM AND METHOD FOR IMPLEMENTING INSTRUMENTED SAFETY SYSTEMS
WO2007100536A1 (en) 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
WO2007146225A2 (en) 2006-06-12 2007-12-21 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2008010481A1 (en) 2006-07-18 2008-01-24 Astellas Pharma Inc. Aminoindan derivative or salt thereof
AU2007293416A1 (en) 2006-09-07 2008-03-13 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease
TW200831484A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
TW200831091A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
WO2008076043A1 (en) 2006-12-20 2008-06-26 Astrazeneca Ab Novel 2-amino-5,5-diaryl-imidazol-4-ones
CL2008000784A1 (es) 2007-03-20 2008-05-30 Wyeth Corp Compuestos amino-5-[-4-(diflourometoxi) fenil sustituido]-5-fenilmidazolona, inhibidores de b-secretasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar alzheimer, deterioro cognitivo, sindrome de down, disminucion co
CL2008000791A1 (es) 2007-03-23 2008-05-30 Wyeth Corp Compuestos derivados de 2-amino-5-(4-difluorometoxi-fenil)-5-fenil-imidazolidin-4-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la actividad bace excesiva, tales como enferm
EP2147914B1 (en) 2007-04-24 2014-06-04 Shionogi&Co., Ltd. Aminodihydrothiazine derivatives substituted with cyclic groups
WO2008133273A1 (ja) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. アルツハイマー症治療用医薬組成物
UY31083A1 (es) 2007-05-15 2009-01-05 Astrazeneca Ab Derivados de sulfoximinas para la inhibicion de b-secretasa
EP2077637B1 (en) 2007-12-12 2020-03-11 Alcatel Lucent System and method for protecting payload information in radio transmission
AU2009216825A1 (en) 2008-02-18 2009-08-27 F. Hoffmann-La Roche Ag 4, 5-dihydro-oxazol-2-yl amine derivatives
TWI431004B (zh) 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
WO2010013302A1 (ja) 2008-07-28 2010-02-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 スピロアミノジヒドロチアジン誘導体
AU2009277485B2 (en) 2008-07-28 2013-05-02 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives
US8450308B2 (en) 2008-08-19 2013-05-28 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
TWI385175B (zh) 2008-09-11 2013-02-11 Amgen Inc 作為β-分泌酶調節劑之螺旋-三環化合物及其使用方法
PE20110777A1 (es) 2008-11-23 2011-10-29 Pfizer Nuevas lactamas como inhibidores de beta secretasa
AU2010223937B2 (en) * 2009-03-13 2015-01-22 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
WO2011072064A1 (en) 2009-12-08 2011-06-16 Array Biopharma Inc. S piro [chroman - 4, 4 ' - imidazol] ones as beta - secretase inhibitors
WO2011106414A1 (en) * 2010-02-24 2011-09-01 Dillard Lawrence W Inhibitors of beta-secretase
US20120065195A1 (en) 2010-03-31 2012-03-15 Clark Christopher T Compounds for treating neurodegenerative diseases
US8415483B2 (en) * 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
TWI557112B (zh) 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β－分泌酶抑制劑

Also Published As

Publication number Publication date
EA201491534A1 (ru) 2014-12-30
AU2013230523A1 (en) 2014-09-18
JP2015511958A (ja) 2015-04-23
ES2568928T3 (es) 2016-05-05
WO2013134085A8 (en) 2014-09-04
SG11201404600VA (en) 2014-10-30
MA35945B1 (fr) 2014-12-01
KR20140138774A (ko) 2014-12-04
CO7091177A2 (es) 2014-10-21
HUE027289T2 (en) 2016-09-28
NZ629239A (en) 2016-04-29
US9949975B2 (en) 2018-04-24
EA024995B1 (ru) 2016-11-30
HRP20160415T1 (hr) 2016-06-03
RS54730B1 (sr) 2016-10-31
UA113641C2 (xx) 2017-02-27
MX2014010625A (es) 2015-04-08
AU2017236042B2 (en) 2019-01-03
IN2014DN06710A (el) 2015-05-22
US20130289050A1 (en) 2013-10-31
UY34654A (es) 2013-09-30
US8981112B2 (en) 2015-03-17
US20150150872A1 (en) 2015-06-04
CN104271558B (zh) 2016-08-24
ECSP14020640A (es) 2015-06-30
ME02390B (me) 2016-09-20
GEP20176799B (en) 2018-01-10
EP2822930A1 (en) 2015-01-14
IL233887A0 (en) 2014-09-30
SMT201600114B (it) 2016-08-31
AP4029A (en) 2017-02-05
CA2864143A1 (en) 2013-09-12
DK2822930T3 (en) 2016-04-25
CN104271558A (zh) 2015-01-07
EP2822930B1 (en) 2016-01-20
US20170196867A1 (en) 2017-07-13
US20180344734A1 (en) 2018-12-06
CA2864143C (en) 2020-04-14
PH12014501963B1 (en) 2014-11-17
MX353432B (es) 2018-01-11
ZA201405846B (en) 2017-08-30
AU2017236042A1 (en) 2017-10-26
PE20141972A1 (es) 2014-12-28
MY171091A (en) 2019-09-25
TW201339139A (zh) 2013-10-01
TN2014000326A1 (en) 2015-12-21
BR112014021269A2 (pt) 2017-07-04
HK1205739A1 (zh) 2015-12-24
SI2822930T1 (sl) 2016-09-30
JP6161643B2 (ja) 2017-07-12
PH12014501963A1 (en) 2014-11-17
AU2013230523B2 (en) 2017-10-05
AR090241A1 (es) 2014-10-29
TWI557112B (zh) 2016-11-11
PL2822930T3 (pl) 2016-09-30
US9526727B2 (en) 2016-12-27
CL2014002334A1 (es) 2015-04-17
WO2013134085A1 (en) 2013-09-12
AP2014007900A0 (en) 2014-08-31
IL233887A (en) 2017-09-28

Similar Documents

Publication Publication Date Title
CY1117543T1 (el) Αναστολεις βητα-σεκρετασης
EA201300669A1 (ru) Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение
EA201590053A1 (ru) Модуляторы пути системы комплемента и их применение
ECSP14013159A (es) Compuestos inhibidores de metaloenzimas
EA201892339A2 (ru) Несиалированный выделенный полипептид, способ получения указанного полипептида и фармацевтическая композиция для лечения воспалительного заболевания
EA201391106A1 (ru) Новые гетероциклические производные
CU20160151A7 (es) 2-AMIN0-6-METI L-4,4a, 5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
EA201600096A1 (ru) Бензил-1н-пиразол[3,4-b]пиридины и их применение
EA201591648A1 (ru) Бензимидазол-2-ил-пиримидиновые модуляторы рецептора гистамина h4
EA201890245A1 (ru) Замещенные 4-азаиндолы и их применение в качестве модуляторов рецептора glun2b
TN2015000032A1 (en) Inhibitors of beta-secretase
EA201691293A1 (ru) Гетероарильные производные бутановой кислоты в качестве ингибиторов lta4h
EA201790519A1 (ru) Терапевтические соединения в качестве ингибиторов рецептора орексина-1
UA108878C2 (ru) Ингибиторы протеинтирозинкиназной активности
BR112015010225A2 (pt) compostos tricíclicos e seus métodos de produção e utilização
BR112018012343A2 (pt) composições de benzofenonas poli-hidroxiladas e métodos de tratamento de distúrbios neurodegenerativos
WO2014052398A8 (en) Inhibitors of beta-secretase
EA201501176A1 (ru) Замещенные бензоксазолы
UA113887C2 (xx) 5-амінотетрагідрохінолін-2-карбонові кислоти і їх застосування
TH153182A (th) ตัวยับยั้งเบต้า-ซีครีเตส
MA37955A1 (fr) Inhibiteurs de bêta-secrétase